Identification of Multi-Target Kinase and Chromatin Regulatory Inhibitors for Amyotrophic Lateral Sclerosis via Bulk Transcriptomic Profiling and Computational Drug Repurposing

Read full text Summarise with VIRAT
Authors: Glen Charles Ritschel, Claude
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Provisional patent specification filed with the United States Patent and Trademark Office (USPTO) by Glen Charles Ritschel, Ritschel Research, Tega Cay, South Carolina (Micro-Entity; Application # 64/016,256; Confirmation # 1999; Patent Center # 75002501; filed March 25, 2026). This specification discloses a computational drug repurposing method applied to bulk RNA sequencing data from ALS patient spinal cord tissue (GSE153960; Prudencio et al., 2020; 1,659 samples). Differential expression analysis identified 28,210 dysregulated genes, from which 65 ChEMBL-tractable targets were extracted spanning kinase signaling (CAMK4, MAP2K6, NRK), chromatin remodeling (RSF1, ING3, SMC3, ARID2, SMCHD1), DNA damage response (USP1, RIF1), and nuclear regulation (RORA, SP3). Screening of 12,165 unique compounds with USPTO prior art verification identified all 12,165 as NOVEL_ALL (100%). Top leads: CHEMBL5653589 (18 targets, score 189.7), MOLIBRESIB (CHEMBL1232461, BET bromodomain inhibitor, 13 targets, score 137.8), SUNITINIB (CHEMBL535, 4 targets, score 46.7). Pipeline code: https://github.com/glenritschel/als-scrna

Fields of Study & Subjects

Computational Drug Discovery Methods Amyotrophic Lateral Sclerosis Research Alzheimer's disease research and treatments

Publication details

Journal / source
Zenodo (CERN European Organization for Nuclear Research)
Publication date
25 March 2026
Language
EN